Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G_0/1 phase

References

• Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643 - 9; http://dx.doi.org/10.1038/25292; PMID: 9872311
   PubMed Web of Science ®Google Scholar
• Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004; 432:338 - 41; http://dx.doi.org/10.1038/nature03099; PMID: 15549096
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791 - 7; http://dx.doi.org/10.1200/JCO.2008.16.0259; PMID: 18695255
   PubMed Web of Science ®Google Scholar
• Heilig CE, Löffler H, Mahlknecht U, Janssen JW, Ho AD, Jauch A, et al. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med 2010; 14:895 - 902; http://dx.doi.org/10.1111/j.1582-4934.2009.00905.x; PMID: 19754665
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010; 116:2224 - 8; http://dx.doi.org/10.1182/blood-2010-02-270330; PMID: 20562328
   PubMed Web of Science ®Google Scholar
• Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988; 54:831 - 40; http://dx.doi.org/10.1016/S0092-8674(88)91175-0; PMID: 2842066
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 1996; 74:1518 - 25; http://dx.doi.org/10.1038/bjc.1996.583; PMID: 8932329
   PubMed Web of Science ®Google Scholar
• Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006; 66:8404 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-06-0683; PMID: 16951150
   PubMed Web of Science ®Google Scholar
• Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101:837 - 45; http://dx.doi.org/10.1182/blood-2002-05-1459; PMID: 12393383
   PubMed Web of Science ®Google Scholar
• Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84:1243 - 8; PMID: 8049440
   PubMed Web of Science ®Google Scholar
• Dreyfus F, Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B. Expression of the Evi-1 gene in myelodysplastic syndromes. Leukemia 1995; 9:203 - 5; PMID: 7845018
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Ohyashiki K, Shimamoto T, Kawakubo K, Fujimura T, Nakazawa S, et al. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. Blood 1995; 85:3713 - 8; PMID: 7780155
   PubMed Web of Science ®Google Scholar
• Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, et al. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 1996; 10:788 - 94; PMID: 8656673
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, et al, MRC Adult Leukaemia Working Party. EVI1 expression in acute myeloid leukaemia. Br J Haematol 2001; 112:208 - 11; http://dx.doi.org/10.1046/j.1365-2141.2001.02569.x; PMID: 11167805
   PubMed Web of Science ®Google Scholar
• Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 2003; 36:80 - 9; http://dx.doi.org/10.1002/gcc.10144; PMID: 12461752
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198 - 204; http://dx.doi.org/10.1038/nm.2088; PMID: 20098431
   PubMed Web of Science ®Google Scholar
• Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28:2101 - 7; http://dx.doi.org/10.1200/JCO.2009.26.0646; PMID: 20308656
   PubMed Web of Science ®Google Scholar
• Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28:3890 - 8; http://dx.doi.org/10.1200/JCO.2010.29.2771; PMID: 20660833
   PubMed Web of Science ®Google Scholar
• Shi G, Weh HJ, Dührsen U, Zeller W, Hossfeld DK. Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies. Cancer Genet Cytogenet 1997; 96:58 - 63; http://dx.doi.org/10.1016/S0165-4608(96)00293-2; PMID: 9209472
   PubMed Web of Science ®Google Scholar
• Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985; 66:1362 - 70; PMID: 4063525
   PubMed Web of Science ®Google Scholar
• Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. Br J Haematol 1993; 83:158 - 65; http://dx.doi.org/10.1111/j.1365-2141.1993.tb04647.x; PMID: 8435325
   PubMed Web of Science ®Google Scholar
• Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994; 8:1318 - 26; PMID: 8057667
   PubMed Web of Science ®Google Scholar
• Horsman DE, Gascoyne RD, Barnett MJ. Acute leukemia with structural rearrangements of chromosome 3. Leuk Lymphoma 1995; 16:369 - 77; http://dx.doi.org/10.3109/10428199509054422; PMID: 7787746
   PubMed Web of Science ®Google Scholar
• Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995; 91:490 - 501; http://dx.doi.org/10.1111/j.1365-2141.1995.tb05329.x; PMID: 8547101
   PubMed Web of Science ®Google Scholar
• Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, et al. Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features. Hematol J 2002; 3:21 - 31; http://dx.doi.org/10.1038/sj.thj.6200143; PMID: 11960392
   PubMedGoogle Scholar
• Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, van den Berg E, van der Blij-Philipsen M, Geurts van Kessel A, et al. Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia 2004; 18:1108 - 14; http://dx.doi.org/10.1038/sj.leu.2403346; PMID: 15085164
   PubMed Web of Science ®Google Scholar
• Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006; 45:349 - 56; http://dx.doi.org/10.1002/gcc.20295; PMID: 16342172
   PubMed Web of Science ®Google Scholar
• Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 2007; 396:346 - 57; http://dx.doi.org/10.1016/j.gene.2007.04.012; PMID: 17507183
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000; 19:2958 - 68; http://dx.doi.org/10.1093/emboj/19.12.2958; PMID: 10856240
   PubMed Web of Science ®Google Scholar
• Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005; 24:1976 - 87; http://dx.doi.org/10.1038/sj.emboj.7600679; PMID: 15889140
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 2006; 25:3565 - 75; http://dx.doi.org/10.1038/sj.onc.1209403; PMID: 16462766
   PubMed Web of Science ®Google Scholar
• Konrad TA, Karger A, Hackl H, Schwarzinger I, Herbacek I, Wieser R. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukoc Biol 2009; 86:813 - 22; http://dx.doi.org/10.1189/jlb.0109042; PMID: 19605700
   PubMed Web of Science ®Google Scholar
• Kilbey A, Alzuherri H, McColl J, Calés C, Frampton J, Bartholomew C. The Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. Br J Haematol 2005; 130:902 - 11; http://dx.doi.org/10.1111/j.1365-2141.2005.05709.x; PMID: 16156860
   PubMed Web of Science ®Google Scholar
• Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460:278 - 82; http://dx.doi.org/10.1038/nature08136; PMID: 19506557
   PubMed Web of Science ®Google Scholar
• Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, et al. Centrosome amplification can initiate tumorigenesis in flies. Cell 2008; 133:1032 - 42; http://dx.doi.org/10.1016/j.cell.2008.05.039; PMID: 18555779
   PubMed Web of Science ®Google Scholar
• Krämer A. Centrosome aberrations--hen or egg in cancer initiation and progression?. Leukemia 2005; 19:1142 - 4; http://dx.doi.org/10.1038/sj.leu.2403780; PMID: 15858612
   PubMed Web of Science ®Google Scholar
• Boutros R, Lobjois V, Ducommun B. CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation. Cancer Res 2007; 67:11557 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-07-2415; PMID: 18089784
   PubMed Web of Science ®Google Scholar
• Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 2005; 7:1140 - 6; http://dx.doi.org/10.1038/ncb1320; PMID: 16244668
   PubMed Web of Science ®Google Scholar
• Leidel S, Delattre M, Cerutti L, Baumer K, Gönczy P. SAS-6 defines a protein family required for centrosome duplication in C. elegans and in human cells. Nat Cell Biol 2005; 7:115 - 25; http://dx.doi.org/10.1038/ncb1220; PMID: 15665853
   PubMed Web of Science ®Google Scholar
• Löffler H, Fechter A, Matuszewska M, Saffrich R, Mistrik M, Marhold J, et al. Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance. Cancer Res 2011; 71:2129 - 39; http://dx.doi.org/10.1158/0008-5472.CAN-10-2684; PMID: 21406398
   PubMed Web of Science ®Google Scholar
• Stevens NR, Roque H, Raff JW. DSas-6 and Ana2 coassemble into tubules to promote centriole duplication and engagement. Dev Cell 2010; 19:913 - 9; http://dx.doi.org/10.1016/j.devcel.2010.11.010; PMID: 21145506
   PubMed Web of Science ®Google Scholar
• Löffler H, Bochtler T, Fritz B, Tews B, Ho AD, Lukas J, et al. DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function. Cell Cycle 2007; 6:2541 - 8; http://dx.doi.org/10.4161/cc.6.20.4810; PMID: 17726372
   PubMed Web of Science ®Google Scholar
• Takada S, Kelkar A, Theurkauf WE. Drosophila checkpoint kinase 2 couples centrosome function and spindle assembly to genomic integrity. Cell 2003; 113:87 - 99; http://dx.doi.org/10.1016/S0092-8674(03)00202-2; PMID: 12679037
   PubMed Web of Science ®Google Scholar
• Bourke E, Dodson H, Merdes A, Cuffe L, Zachos G, Walker M, et al. DNA damage induces Chk1-dependent centrosome amplification. EMBO Rep 2007; 8:603 - 9; http://dx.doi.org/10.1038/sj.embor.7400962; PMID: 17468739
   PubMed Web of Science ®Google Scholar
• Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002; 21:483 - 92; http://dx.doi.org/10.1093/emboj/21.4.483; PMID: 11847097
   PubMed Web of Science ®Google Scholar
• Guarguaglini G, Duncan PI, Stierhof YD, Holmström T, Duensing S, Nigg EA. The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell 2005; 16:1095 - 107; http://dx.doi.org/10.1091/mbc.E04-10-0939; PMID: 15616186
   PubMed Web of Science ®Google Scholar
• Löffler H, Fechter A, Liu FY, Poppelreuther S, Krämer A. DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites. Oncogene 2012; http://dx.doi.org/10.1038/onc.2012.310; PMID: 22824794
   PubMed Web of Science ®Google Scholar
• Vulprecht J, David A, Tibelius A, Castiel A, Konotop G, Liu F, et al. STIL is required for centriole duplication in human cells. J Cell Sci 2012; 125:1353 - 62; http://dx.doi.org/10.1242/jcs.104109; PMID: 22349705
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23:7212 - 20; http://dx.doi.org/10.1200/JCO.2005.07.501; PMID: 16192605
   PubMed Web of Science ®Google Scholar
• Kilbey A, Stephens V, Bartholomew C. Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. Cell Growth Differ 1999; 10:601 - 10
   PubMedGoogle Scholar
• Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. J Cell Sci 2008; 121:3859 - 66; http://dx.doi.org/10.1242/jcs.039537; PMID: 19020304
   PubMed Web of Science ®Google Scholar
• Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha K, Giles HR, et al. Model for the genetic evolution of human solid tumors. Cancer Res 1989; 49:3344 - 54; PMID: 2720687
   PubMed Web of Science ®Google Scholar
• Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25:217 - 22; http://dx.doi.org/10.1038/76095; PMID: 10835641
   PubMed Web of Science ®Google Scholar
• Lukas J, Bartek J. Immunoprecipitation of proteins under nondenaturing conditions. In: Celis JE, ed. Cell Biology: A Laboratory Handbook. San Diego: Academic Press, 1998:489-94.
   Google Scholar